Feb-17-21 Downgrade
JP Morgan
Overweight → Neutral
$76 → $39
Feb-16-21 Downgrade
William Blair
Outperform → Mkt Perform
Feb-16-21 Downgrade
Wedbush
Outperform → Neutral
Feb-16-21 Downgrade
BofA Securities
Buy → Neutral
Dec-09-20 Downgrade
Maxim Group
Buy → Hold
Nov-11-20 Initiated
Berenberg
Buy
Nov-05-20 Downgrade
Stifel
Buy → Hold
$77 → $51
Nov-05-20 Downgrade
BMO Capital Markets
Outperform → Market Perform
$108 → $56
Nov-05-20 Downgrade
Barclays
Overweight → Equal Weight
Nov-02-20 Upgrade
William Blair
Mkt Perform → Outperform
Oct-20-20 Initiated
Mizuho
Buy
$123
May-13-20 Initiated
RBC Capital Mkts
Outperform
$100
Mar-27-20 Upgrade
Stifel
Hold → Buy
$70
Feb-19-20 Downgrade
Raymond James
Strong Buy → Mkt Perform
Feb-19-20 Downgrade
Raymond James
Outperform → Mkt Perform
Feb-03-20 Upgrade
Evercore ISI
In-line → Outperform
$86 → $100
Feb-03-20 Resumed
BofA/Merrill
Buy
$120
Dec-13-19 Upgrade
Oppenheimer
Perform → Outperform
$135
Nov-26-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
$119
Nov-19-19 Downgrade
Evercore ISI
Outperform → In-line
$86
Mar-03-21 07:30AM
06:30AM
03:00AM
Mar-02-21 01:45PM
01:15PM
12:30PM
11:38AM
11:00AM
06:13AM
Mar-01-21 11:54PM
01:45PM
12:40PM
12:00PM
10:57AM
09:32AM
06:30AM
12:20AM
Feb-28-21 10:30AM
01:06AM
Feb-27-21 02:00PM
Feb-26-21 08:00AM
Feb-25-21 04:59PM
03:00PM
12:33PM
11:00AM
11:00AM
Feb-24-21 08:26PM
07:00PM
05:53PM
05:30PM
02:30PM
02:14PM
01:19PM
12:15PM
12:00PM
11:15AM
11:00AM
11:00AM
10:24AM
06:56AM
Feb-23-21 06:33PM
05:24PM
04:05PM
03:20PM
02:39PM
01:37PM
12:30PM
12:00PM
11:15AM
05:38AM
Feb-22-21 04:05PM
02:57PM
01:22PM
01:20PM
12:05PM
11:55AM
11:00AM
11:00AM
10:16AM
Feb-21-21 10:30AM
Feb-20-21 06:45PM
02:51PM
07:50AM
Feb-19-21 01:58PM
12:30PM
12:00PM
11:00AM
10:55AM
09:00AM
08:00AM
12:05AM
Feb-18-21 11:59PM
09:39PM
06:16PM
02:58PM
01:26PM
12:00PM
11:49AM
11:30AM
11:03AM
10:00AM
06:30AM
Feb-17-21 11:27PM
09:29PM
08:00PM
07:38PM
07:11PM
06:41PM
05:41PM
04:35PM
01:45PM
12:45PM
11:45AM
11:00AM
08:19AM
Feb-16-21 05:42PM
04:20PM Investor's Business Daily
02:55PM
02:30PM
01:13PM
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Cole Jason Chief Operating and Feb 17 Sale 28.16 665 18,727 48,035 Feb 18 05:22 PM Davidson David Chief Medical Officer Feb 17 Sale 28.16 698 19,657 47,871 Feb 18 05:22 PM Obenshain Andrew President of SGD Feb 17 Sale 28.16 749 21,093 40,200 Feb 18 05:22 PM Gregory Philip D Chief Scientific Officer Feb 17 Sale 28.16 664 18,699 46,946 Feb 18 05:22 PM Burnett Katy Principal Accounting Officer Feb 17 Sale 28.16 518 14,588 4,097 Feb 18 05:22 PM Baird William D III Chief Financial Officer Feb 17 Sale 28.16 693 19,516 35,529 Feb 18 05:22 PM Baird William D III Chief Financial Officer Feb 12 Sale 45.52 1,216 55,352 21,581 Feb 17 05:23 PM Obenshain Andrew President of SGD Feb 02 Sale 45.93 34 1,561 23,884 Feb 04 04:04 PM Gregory Philip D Chief Scientific Officer Feb 02 Sale 45.93 59 2,710 32,948 Feb 04 04:03 PM Cole Jason Chief Operating and Feb 02 Sale 45.93 38 1,745 32,785 Feb 04 04:03 PM Leschly Nick President and CEO Feb 02 Sale 45.93 594 27,280 86,669 Feb 04 04:04 PM Davidson David Chief Medical Officer Feb 02 Sale 45.93 63 2,893 36,298 Feb 04 04:04 PM Leschly Nick President and CEO Jan 06 Sale 45.05 10,095 454,814 87,263 Jan 08 06:18 PM Smith-Farrell Joanne COO, Oncology Jan 06 Sale 45.05 1,287 57,984 20,609 Jan 08 05:56 PM Cole Jason Chief Operating and Jan 06 Sale 45.05 2,358 106,236 32,823 Jan 08 05:56 PM Davidson David Chief Medical Officer Jan 06 Sale 45.05 3,167 142,684 36,361 Jan 08 05:57 PM FINGER ALISON CECILY Chief Commercial Officer Jan 06 Sale 45.05 1,814 81,727 25,103 Jan 08 05:57 PM Baird William D III Chief Financial Officer Jan 06 Sale 45.05 949 42,756 22,797 Jan 08 05:57 PM Gregory Philip D Chief Scientific Officer Jan 06 Sale 45.05 2,754 124,077 33,007 Jan 08 05:56 PM Leschly Nick President and CEO Jan 05 Sale 44.95 333 14,969 97,358 Jan 08 06:18 PM Smith-Farrell Joanne COO, Oncology Jan 05 Sale 44.95 42 1,888 21,896 Jan 08 05:56 PM Cole Jason Chief Operating and Jan 05 Sale 44.95 43 1,933 35,181 Jan 08 05:56 PM Davidson David Chief Medical Officer Jan 05 Sale 44.95 48 2,158 39,528 Jan 08 05:57 PM FINGER ALISON CECILY Chief Commercial Officer Jan 05 Sale 44.95 40 1,798 26,917 Jan 08 05:57 PM Gregory Philip D Chief Scientific Officer Jan 05 Sale 44.95 45 2,023 35,761 Jan 08 05:56 PM Burnett Katy Principal Accounting Officer Dec 03 Sale 46.09 123 5,669 1,460 Dec 04 04:49 PM Davidson David Chief Medical Officer Dec 02 Sale 46.20 64 2,957 39,576 Dec 04 04:48 PM Gregory Philip D Chief Scientific Officer Dec 02 Sale 46.20 59 2,726 35,806 Dec 04 04:48 PM Cole Jason Chief Operating and Dec 02 Sale 46.20 38 1,756 35,224 Dec 04 04:48 PM Smith-Farrell Joanne COO, Oncology Dec 02 Sale 46.20 38 1,756 21,938 Dec 04 04:48 PM FINGER ALISON CECILY Chief Commercial Officer Dec 02 Sale 46.20 36 1,663 26,957 Dec 04 04:48 PM Leschly Nick President and CEO Dec 02 Sale 46.20 444 20,512 97,691 Dec 04 04:48 PM Leschly Nick President and CEO Nov 02 Sale 52.94 444 23,506 98,135 Nov 04 04:04 PM Davidson David Chief Medical Officer Nov 02 Sale 52.94 63 3,335 39,640 Nov 04 04:05 PM Gregory Philip D Chief Scientific Officer Nov 02 Sale 52.93 59 3,123 35,865 Nov 04 04:05 PM Cole Jason Chief Operating and Nov 02 Sale 52.97 37 1,960 35,262 Nov 04 04:05 PM Smith-Farrell Joanne COO, Oncology Nov 02 Sale 52.97 37 1,960 21,976 Nov 04 04:05 PM FINGER ALISON CECILY Chief Commercial Officer Nov 02 Sale 52.99 35 1,855 26,993 Nov 04 04:05 PM Davidson David Chief Medical Officer Oct 02 Sale 52.77 64 3,377 39,703 Oct 06 04:06 PM Gregory Philip D Chief Scientific Officer Oct 02 Sale 52.77 60 3,166 35,924 Oct 06 04:05 PM Leschly Nick President and CEO Oct 02 Sale 52.77 450 23,744 98,579 Oct 06 04:05 PM FINGER ALISON CECILY Chief Commercial Officer Oct 02 Sale 52.77 36 1,900 27,028 Oct 06 04:05 PM Smith-Farrell Joanne Chief Business Officer Oct 02 Sale 52.77 38 2,005 22,013 Oct 06 04:06 PM Cole Jason Chief Operating and Oct 02 Sale 52.77 38 2,005 35,299 Oct 06 04:06 PM Davidson David Chief Medical Officer Sep 03 Sale 58.60 41 2,403 39,767 Sep 08 04:07 PM Gregory Philip D Chief Scientific Officer Sep 03 Sale 58.60 58 3,399 35,984 Sep 08 04:08 PM Cole Jason Chief Operating and Sep 03 Sale 58.60 36 2,110 35,337 Sep 08 04:08 PM Smith-Farrell Joanne Chief Business Officer Sep 03 Sale 58.60 36 2,110 22,051 Sep 08 04:08 PM FINGER ALISON CECILY Chief Commercial Officer Sep 03 Sale 58.60 35 2,051 27,063 Sep 08 04:08 PM Leschly Nick President and CEO Sep 03 Sale 58.60 431 25,257 99,029 Sep 08 04:07 PM Smith-Farrell Joanne Chief Business Officer Aug 25 Sale 58.95 225 13,264 22,087 Aug 27 05:11 PM WENTWORTH KORY JAMES Principal Accounting Officer Aug 03 Sale 61.00 82 5,002 9,512 Aug 05 04:06 PM Smith-Farrell Joanne Chief Business Officer Aug 03 Sale 60.48 37 2,238 22,312 Aug 05 04:05 PM Cole Jason Chief Operating and Aug 03 Sale 60.48 37 2,238 35,373 Aug 05 04:05 PM Leschly Nick President and CEO Aug 03 Sale 60.49 444 26,856 99,460 Aug 05 04:05 PM Davidson David Chief Medical Officer Aug 03 Sale 60.75 42 2,552 39,808 Aug 05 04:06 PM Gregory Philip D Chief Scientific Officer Aug 03 Sale 60.49 59 3,569 36,042 Aug 05 04:05 PM FINGER ALISON CECILY Chief Commercial Officer Aug 03 Sale 60.49 35 2,117 27,098 Aug 05 04:05 PM WENTWORTH KORY JAMES Principal Accounting Officer Jul 20 Sale 66.38 596 39,562 9,594 Jul 22 05:22 PM Smith-Farrell Joanne Chief Business Officer Jul 02 Sale 61.57 38 2,340 22,349 Jul 07 05:17 PM Leschly Nick President and CEO Jul 02 Sale 61.57 443 27,277 99,904 Jul 07 05:19 PM Cole Jason Chief Operating and Jul 02 Sale 61.57 38 2,340 35,410 Jul 07 05:18 PM Davidson David Chief Medical Officer Jul 02 Sale 61.57 42 2,586 39,850 Jul 07 05:22 PM Gregory Philip D Chief Scientific Officer Jul 02 Sale 61.57 59 3,633 36,101 Jul 07 05:15 PM FINGER ALISON CECILY Chief Commercial Officer Jul 02 Sale 61.57 36 2,217 27,133 Jul 07 05:16 PM Smith-Farrell Joanne Chief Business Officer Jun 04 Sale 65.23 170 11,089 22,387 Jun 08 04:24 PM WENTWORTH KORY JAMES Principal Accounting Officer Jun 04 Sale 65.23 154 10,045 10,190 Jun 08 04:24 PM Davidson David Chief Medical Officer Jun 02 Sale 64.03 42 2,689 39,892 Jun 04 05:44 PM Cole Jason Chief Operating and Jun 02 Sale 64.03 38 2,433 35,448 Jun 04 05:44 PM Smith-Farrell Joanne Chief Business Officer Jun 02 Sale 64.03 37 2,369 22,557 Jun 04 05:44 PM Gregory Philip D Chief Scientific Officer Jun 02 Sale 64.03 59 3,778 36,160 Jun 04 05:43 PM FINGER ALISON CECILY Chief Commercial Officer Jun 02 Sale 64.04 35 2,241 27,169 Jun 04 05:44 PM Leschly Nick President and CEO Jun 02 Sale 64.04 444 28,433 100,347 Jun 04 05:44 PM Smith-Farrell Joanne Chief Business Officer May 04 Sale 50.17 232 11,639 22,594 May 05 04:05 PM Smith-Farrell Joanne Chief Business Officer Apr 06 Sale 43.73 583 25,495 21,393 Apr 08 04:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite